分子诊断胶质母细胞瘤的临床表现与结局
p=0.411),倾向性评分匹配后生存无显著差异(517 vs 468天,p=0.670)。molGBM生存优于相应级别的IDH突变型星形细胞瘤(p<0.001)。
要点
- 分子诊断胶质母细胞瘤具有独特临床影像表型,但生存优势受基线差异影响。
- 校正年龄和KPS后,分子诊断并非独立生存预测因素。
- 分子诊断胶质母细胞瘤生存仍差于同级IDH突变型星形细胞瘤。
核心结论
- 分子诊断胶质母细胞瘤呈现独特临床影像表型,其相对组织学诊断胶质母细胞瘤的生存优势受基线临床差异影响。
研究设计与样本
- 分子诊断胶质母细胞瘤按组织学分级分层,并与相应级别的IDH突变型星形细胞瘤比较。
- 采用Kaplan-Meier分析、Cox回归和倾向性评分匹配评估生存。
主要发现
- 分子诊断胶质母细胞瘤患者更年轻(p<0.001)、KPS更高(p<0.001)、更常以癫痫起病(p=0.006),而局灶性神经功能缺损在组织学诊断组更常见。
- 分子诊断组对比增强更少(p<0.001),Ki-67指数更低(p<0.001)。
- 分子诊断组中位总生存期长于组织学诊断组(539 vs 374天;p=0.032)。
- 校正年龄和KPS后,肿瘤分组与生存无独立关联(HR 1.21,95%CI 0.77-1.90;p=0.411)。
- 倾向性评分匹配队列中总生存无显著差异(517 vs 468天;p=0.670),分子诊断组生存劣于相应级别IDH突变型星形细胞瘤(p<0.001)。
临床怎么用
- 分子诊断胶质母细胞瘤患者基线功能状态较好,临床表现常以癫痫起病,应结合分子特征进行个体化评估。
- 生存预后判断需综合考虑年龄和KPS等基线因素,分子诊断本身并非独立预后因素。
- 分子诊断胶质母细胞瘤预后仍差于同级IDH突变型星形细胞瘤,治疗决策应参考IDH状态。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The 2021 WHO classification permits diagnosis of glioblastoma in IDH-wildtype diffuse astrocytic tumors with TERT promoter mutation, EGFR amplification, or chromosome 7 gain/10 loss, even without necrosis or microvascular proliferation. The clinical behavior of these molecularly defined glioblastomas (molGBM) remains uncertain. METHODS: We retrospectively analyzed patients with molGBM treated at Hannover Medical School between 2017 and 2024. A contemporaneous histologically defined glioblastoma cohort (hisGBM) served as a control group in an approximately 1:3 ratio. MolGBM were stratified by histological grade and additionally compared with IDH-mutant astrocytomas of corresponding grade. Survival was assessed using Kaplan-Meier analysis, Cox regression, and propensity score matching. RESULTS: Thirty-four patients with molGBM and 103 with hisGBM were included. Compared with hisGBM, molGBM patients were younger (p < 0.001), had higher Karnofsky Performance Status (p < 0.001), and more often presented with seizures (p = 0.006), whereas focal neurological deficits were more frequent in hisGBM. MolGBM showed less contrast enhancement (p < 0.001) and lower Ki-67 indices (p < 0.001). Median overall survival was longer in molGBM (539 vs. 374 days; p = 0.032), but tumor group was not independently associated with survival after adjustment for age and KPS (HR 1.21, 95% CI 0.77-1.90; p = 0.411). In the matched cohort, overall survival did not differ significantly (517 vs. 468 days; p = 0.670). MolGBM had inferior survival to grade-corresponding IDH-mutant astrocytomas (p < 0.001). CONCLUSIONS: MolGBM shows a distinct clinical-radiological phenotype, while its apparent survival advantage over hisGBM is influenced by baseline clinical differences. CLINICAL TRIAL NUMBER: Not applicable.
引用
- Hounchonou HF, Polemikos M, Pirayesh A, et al. Molecularly diagnosed glioblastoma: clinical presentation and outcomes. J Neurooncol. 2026. PMID: 42567974. doi:10.1007/s11060-026-05752-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。